Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program
JB Bussel, DM Arnold, MA Boxer… - American journal of …, 2019 - Wiley Online Library
Two randomized, double‐blind, placebo‐controlled studies demonstrated responses (≥ 50
000/μL) to fostamatinib in adults with long‐standing immune thrombocytopenia (ITP). The …
000/μL) to fostamatinib in adults with long‐standing immune thrombocytopenia (ITP). The …
Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program.
JB Bussel, DM Arnold, MA Boxer, N Cooper… - American Journal of …, 2019 - europepmc.org
Two randomized, double‐blind, placebo‐controlled studies demonstrated responses (≥ 50
000/μL) to fostamatinib in adults with long‐standing immune thrombocytopenia (ITP). The …
000/μL) to fostamatinib in adults with long‐standing immune thrombocytopenia (ITP). The …
Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program
JB Bussel, DM Arnold, MA Boxer, N Cooper… - American Journal of …, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Two randomized, double‐blind, placebo‐
controlled studies demonstrated responses (≥ 50 000/μL) to fostamatinib in adults with long …
controlled studies demonstrated responses (≥ 50 000/μL) to fostamatinib in adults with long …
Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program
JB Bussel, DM Arnold, MA Boxer… - American journal …, 2019 - pubmed.ncbi.nlm.nih.gov
Two randomized, double-blind, placebo-controlled studies demonstrated responses (≥ 50
000/μL) to fostamatinib in adults with long-standing immune thrombocytopenia (ITP). The …
000/μL) to fostamatinib in adults with long-standing immune thrombocytopenia (ITP). The …
[HTML][HTML] Long‐term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program
JB Bussel, DM Arnold, MA Boxer… - American Journal of …, 2019 - ncbi.nlm.nih.gov
Two randomized, double‐blind, placebo‐controlled studies demonstrated responses (≥ 50
000/μL) to fostamatinib in adults with long‐standing immune thrombocytopenia (ITP). The …
000/μL) to fostamatinib in adults with long‐standing immune thrombocytopenia (ITP). The …